About
Orally-active small molecules
Areas of Focus
Categories
Small Molecule PharmaceuticalBiotech
Team (4)
Clinical Trials (11)
View allTotal Trials
11
As Lead Sponsor
6
As Collaborator
5
Total Enrollment
643
By Phase
PHASE2: 6PHASE1: 3PHASE1/PHASE2: 2
By Status
RECRUITING: 4WITHDRAWN: 2COMPLETED: 2ACTIVE_NOT_RECRUITING: 1ENROLLING_BY_INVITATION: 1TERMINATED: 1
Clinical Trials Pipeline11 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
Today
Hover over trial bars to see details
Recent Trials
NCT06922318Collaborator
The COSMYC Trial (COmbined Suppression of MYC)
PHASE2Recruiting
50 participants
Started: Aug 19, 2025 · Completed: Aug 30, 2031
NCT06161493Collaborator
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
PHASE1Withdrawn
Started: Jan 23, 2024 · Completed: Dec 31, 2029
NCT05071937Collaborator
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
PHASE2Recruiting
33 participants
Started: Apr 21, 2023 · Completed: Mar 1, 2033
NCT05607108Collaborator
A Study of ZEN003694 in People With Squamous Cell Lung Cancer
PHASE2Recruiting
25 participants
Started: Nov 1, 2022 · Completed: Nov 30, 2025
NCT04986423Lead Sponsor
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
PHASE2Recruiting
200 participants
Started: Sep 8, 2021 · Completed: Jun 30, 2026
Locations (1)
Headquarters
San Francisco, CA, United States
Map
Loading map...